Medical implications from the crystal structure of a copper-containing amine oxidase complexed with the antidepressant drug tranylcypromine
The X-ray crystal structure of the copper-containing quinoprotein amine oxidase from E. coli has been determined in complex with the antidepressant drug tranylcypromine to 2.4 Å resolution. The drug is a racemic mix of two enantiomers, but only one is seen bound to the enzyme. The other enantiomer i...
Gespeichert in:
| Veröffentlicht in: | FEBS letters 2004-10, Vol.576 (3), p.301-305 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 305 |
|---|---|
| container_issue | 3 |
| container_start_page | 301 |
| container_title | FEBS letters |
| container_volume | 576 |
| creator | Wilmot, Carrie M. Saysell, Colin G. Blessington, Aidan Conn, Danyl A. Kurtis, Christian R. McPherson, Michael J. Knowles, Peter F. Phillips, Simon E.V. |
| description | The X-ray crystal structure of the copper-containing quinoprotein amine oxidase from
E. coli has been determined in complex with the antidepressant drug tranylcypromine to 2.4 Å resolution. The drug is a racemic mix of two enantiomers, but only one is seen bound to the enzyme. The other enantiomer is not acting as a substrate for the enzyme as no catalytic activity was detected when the enzyme was initially exposed to the drug. The inhibition of human copper amine oxidases could be a source of side-effects in its use as an antidepressant to inhibit the flavin-containing monoamine oxidases in the brain. |
| doi_str_mv | 10.1016/j.febslet.2004.09.031 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66994806</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014579304011378</els_id><sourcerecordid>66994806</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5048-41cb4ef89a14b76f09df3341a58153c8e3d9325b85a2153dd5de403276f43c8e3</originalsourceid><addsrcrecordid>eNqNkcFu1DAQhi0EokvhEUA-cUuwYztrnxBULUUq4gCcLceetF4lTrCdtnkGXhpvd6Ue25PHM___j-UPofeU1JTQ9tOu7qFLA-S6IYTXRNWE0RdoQ-WWVYy38iXaEEJ5JbaKnaA3Ke1IuUuqXqMTKriSQjQb9O8HOG_NgP04D6XIfgoJ93Eacb4BbOOacpmmHBeblwh46rHBdppniJWdQjY--HCNzehDGd57Z1KxTSUN7sHhO59vHpJMyN7BHCGlUmIXl2ucownrYNe5rCv2t-hVb4YE747nKfpzcf777LK6-vnt-9mXq8oKwmXFqe049FIZyrtt2xPlesY4NUJSwawE5hRrRCeFaUrDOeGAE9YUKX8Yn6KPh9yy9-8CKevRJwvDYAJMS9JtqxSXpH1S2BCumlawIhQHoY1TShF6PUc_mrhqSvQel97pIy69x6WJ0gVX8X04Lli6Edyj68inCC4Pgjs_wPq8VH1x_rX5tWe_R084oZRtZYn6fIiC8rW3HqJO1kOwhX8Em7Wb_BOv_Q_utcHn</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20492653</pqid></control><display><type>article</type><title>Medical implications from the crystal structure of a copper-containing amine oxidase complexed with the antidepressant drug tranylcypromine</title><source>MEDLINE</source><source>Wiley Online Library Free Content</source><source>Access via Wiley Online Library</source><source>Access via ScienceDirect (Elsevier)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Wilmot, Carrie M. ; Saysell, Colin G. ; Blessington, Aidan ; Conn, Danyl A. ; Kurtis, Christian R. ; McPherson, Michael J. ; Knowles, Peter F. ; Phillips, Simon E.V.</creator><creatorcontrib>Wilmot, Carrie M. ; Saysell, Colin G. ; Blessington, Aidan ; Conn, Danyl A. ; Kurtis, Christian R. ; McPherson, Michael J. ; Knowles, Peter F. ; Phillips, Simon E.V.</creatorcontrib><description>The X-ray crystal structure of the copper-containing quinoprotein amine oxidase from
E. coli has been determined in complex with the antidepressant drug tranylcypromine to 2.4 Å resolution. The drug is a racemic mix of two enantiomers, but only one is seen bound to the enzyme. The other enantiomer is not acting as a substrate for the enzyme as no catalytic activity was detected when the enzyme was initially exposed to the drug. The inhibition of human copper amine oxidases could be a source of side-effects in its use as an antidepressant to inhibit the flavin-containing monoamine oxidases in the brain.</description><identifier>ISSN: 0014-5793</identifier><identifier>EISSN: 1873-3468</identifier><identifier>DOI: 10.1016/j.febslet.2004.09.031</identifier><identifier>PMID: 15498552</identifier><language>eng</language><publisher>England: Elsevier B.V</publisher><subject>2-HP, 2-hydrazinopyridine ; AGE, advanced glycation endproduct ; Amine oxidase ; Amine Oxidase (Copper-Containing) - chemistry ; Amine Oxidase (Copper-Containing) - metabolism ; Antidepressive Agents - chemistry ; Antidepressive Agents - metabolism ; Binding Sites ; Copper metalloprotein ; Crystallography, X-Ray - methods ; CuAO, copper-containing amine oxidase ; ECAO, Escherichia coli amine oxidase ; Escherichia coli ; Escherichia coli - enzymology ; HuPAO, human plasma amine oxidase ; MAOI, flavin-containing monoamine oxidase inhibitor ; Models, Molecular ; Quinoprotein ; TCA, tricyclic antidepressant ; TCP, tranylcypromine ; TPQ, 2,4,5-trihydroxyphenylalanine quinone ; Tranylcypromine ; Tranylcypromine - chemistry ; Tranylcypromine - metabolism ; X-ray crystallography</subject><ispartof>FEBS letters, 2004-10, Vol.576 (3), p.301-305</ispartof><rights>2004 Federation of European Biochemical Societies</rights><rights>FEBS Letters 576 (2004) 1873-3468 © 2015 Federation of European Biochemical Societies</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5048-41cb4ef89a14b76f09df3341a58153c8e3d9325b85a2153dd5de403276f43c8e3</citedby><cites>FETCH-LOGICAL-c5048-41cb4ef89a14b76f09df3341a58153c8e3d9325b85a2153dd5de403276f43c8e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1016%2Fj.febslet.2004.09.031$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.febslet.2004.09.031$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,1417,1433,3550,27924,27925,45574,45575,45995,46409,46833</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15498552$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wilmot, Carrie M.</creatorcontrib><creatorcontrib>Saysell, Colin G.</creatorcontrib><creatorcontrib>Blessington, Aidan</creatorcontrib><creatorcontrib>Conn, Danyl A.</creatorcontrib><creatorcontrib>Kurtis, Christian R.</creatorcontrib><creatorcontrib>McPherson, Michael J.</creatorcontrib><creatorcontrib>Knowles, Peter F.</creatorcontrib><creatorcontrib>Phillips, Simon E.V.</creatorcontrib><title>Medical implications from the crystal structure of a copper-containing amine oxidase complexed with the antidepressant drug tranylcypromine</title><title>FEBS letters</title><addtitle>FEBS Lett</addtitle><description>The X-ray crystal structure of the copper-containing quinoprotein amine oxidase from
E. coli has been determined in complex with the antidepressant drug tranylcypromine to 2.4 Å resolution. The drug is a racemic mix of two enantiomers, but only one is seen bound to the enzyme. The other enantiomer is not acting as a substrate for the enzyme as no catalytic activity was detected when the enzyme was initially exposed to the drug. The inhibition of human copper amine oxidases could be a source of side-effects in its use as an antidepressant to inhibit the flavin-containing monoamine oxidases in the brain.</description><subject>2-HP, 2-hydrazinopyridine</subject><subject>AGE, advanced glycation endproduct</subject><subject>Amine oxidase</subject><subject>Amine Oxidase (Copper-Containing) - chemistry</subject><subject>Amine Oxidase (Copper-Containing) - metabolism</subject><subject>Antidepressive Agents - chemistry</subject><subject>Antidepressive Agents - metabolism</subject><subject>Binding Sites</subject><subject>Copper metalloprotein</subject><subject>Crystallography, X-Ray - methods</subject><subject>CuAO, copper-containing amine oxidase</subject><subject>ECAO, Escherichia coli amine oxidase</subject><subject>Escherichia coli</subject><subject>Escherichia coli - enzymology</subject><subject>HuPAO, human plasma amine oxidase</subject><subject>MAOI, flavin-containing monoamine oxidase inhibitor</subject><subject>Models, Molecular</subject><subject>Quinoprotein</subject><subject>TCA, tricyclic antidepressant</subject><subject>TCP, tranylcypromine</subject><subject>TPQ, 2,4,5-trihydroxyphenylalanine quinone</subject><subject>Tranylcypromine</subject><subject>Tranylcypromine - chemistry</subject><subject>Tranylcypromine - metabolism</subject><subject>X-ray crystallography</subject><issn>0014-5793</issn><issn>1873-3468</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkcFu1DAQhi0EokvhEUA-cUuwYztrnxBULUUq4gCcLceetF4lTrCdtnkGXhpvd6Ue25PHM___j-UPofeU1JTQ9tOu7qFLA-S6IYTXRNWE0RdoQ-WWVYy38iXaEEJ5JbaKnaA3Ke1IuUuqXqMTKriSQjQb9O8HOG_NgP04D6XIfgoJ93Eacb4BbOOacpmmHBeblwh46rHBdppniJWdQjY--HCNzehDGd57Z1KxTSUN7sHhO59vHpJMyN7BHCGlUmIXl2ucownrYNe5rCv2t-hVb4YE747nKfpzcf777LK6-vnt-9mXq8oKwmXFqe049FIZyrtt2xPlesY4NUJSwawE5hRrRCeFaUrDOeGAE9YUKX8Yn6KPh9yy9-8CKevRJwvDYAJMS9JtqxSXpH1S2BCumlawIhQHoY1TShF6PUc_mrhqSvQel97pIy69x6WJ0gVX8X04Lli6Edyj68inCC4Pgjs_wPq8VH1x_rX5tWe_R084oZRtZYn6fIiC8rW3HqJO1kOwhX8Em7Wb_BOv_Q_utcHn</recordid><startdate>20041022</startdate><enddate>20041022</enddate><creator>Wilmot, Carrie M.</creator><creator>Saysell, Colin G.</creator><creator>Blessington, Aidan</creator><creator>Conn, Danyl A.</creator><creator>Kurtis, Christian R.</creator><creator>McPherson, Michael J.</creator><creator>Knowles, Peter F.</creator><creator>Phillips, Simon E.V.</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>20041022</creationdate><title>Medical implications from the crystal structure of a copper-containing amine oxidase complexed with the antidepressant drug tranylcypromine</title><author>Wilmot, Carrie M. ; Saysell, Colin G. ; Blessington, Aidan ; Conn, Danyl A. ; Kurtis, Christian R. ; McPherson, Michael J. ; Knowles, Peter F. ; Phillips, Simon E.V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5048-41cb4ef89a14b76f09df3341a58153c8e3d9325b85a2153dd5de403276f43c8e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>2-HP, 2-hydrazinopyridine</topic><topic>AGE, advanced glycation endproduct</topic><topic>Amine oxidase</topic><topic>Amine Oxidase (Copper-Containing) - chemistry</topic><topic>Amine Oxidase (Copper-Containing) - metabolism</topic><topic>Antidepressive Agents - chemistry</topic><topic>Antidepressive Agents - metabolism</topic><topic>Binding Sites</topic><topic>Copper metalloprotein</topic><topic>Crystallography, X-Ray - methods</topic><topic>CuAO, copper-containing amine oxidase</topic><topic>ECAO, Escherichia coli amine oxidase</topic><topic>Escherichia coli</topic><topic>Escherichia coli - enzymology</topic><topic>HuPAO, human plasma amine oxidase</topic><topic>MAOI, flavin-containing monoamine oxidase inhibitor</topic><topic>Models, Molecular</topic><topic>Quinoprotein</topic><topic>TCA, tricyclic antidepressant</topic><topic>TCP, tranylcypromine</topic><topic>TPQ, 2,4,5-trihydroxyphenylalanine quinone</topic><topic>Tranylcypromine</topic><topic>Tranylcypromine - chemistry</topic><topic>Tranylcypromine - metabolism</topic><topic>X-ray crystallography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wilmot, Carrie M.</creatorcontrib><creatorcontrib>Saysell, Colin G.</creatorcontrib><creatorcontrib>Blessington, Aidan</creatorcontrib><creatorcontrib>Conn, Danyl A.</creatorcontrib><creatorcontrib>Kurtis, Christian R.</creatorcontrib><creatorcontrib>McPherson, Michael J.</creatorcontrib><creatorcontrib>Knowles, Peter F.</creatorcontrib><creatorcontrib>Phillips, Simon E.V.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>FEBS letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wilmot, Carrie M.</au><au>Saysell, Colin G.</au><au>Blessington, Aidan</au><au>Conn, Danyl A.</au><au>Kurtis, Christian R.</au><au>McPherson, Michael J.</au><au>Knowles, Peter F.</au><au>Phillips, Simon E.V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Medical implications from the crystal structure of a copper-containing amine oxidase complexed with the antidepressant drug tranylcypromine</atitle><jtitle>FEBS letters</jtitle><addtitle>FEBS Lett</addtitle><date>2004-10-22</date><risdate>2004</risdate><volume>576</volume><issue>3</issue><spage>301</spage><epage>305</epage><pages>301-305</pages><issn>0014-5793</issn><eissn>1873-3468</eissn><abstract>The X-ray crystal structure of the copper-containing quinoprotein amine oxidase from
E. coli has been determined in complex with the antidepressant drug tranylcypromine to 2.4 Å resolution. The drug is a racemic mix of two enantiomers, but only one is seen bound to the enzyme. The other enantiomer is not acting as a substrate for the enzyme as no catalytic activity was detected when the enzyme was initially exposed to the drug. The inhibition of human copper amine oxidases could be a source of side-effects in its use as an antidepressant to inhibit the flavin-containing monoamine oxidases in the brain.</abstract><cop>England</cop><pub>Elsevier B.V</pub><pmid>15498552</pmid><doi>10.1016/j.febslet.2004.09.031</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0014-5793 |
| ispartof | FEBS letters, 2004-10, Vol.576 (3), p.301-305 |
| issn | 0014-5793 1873-3468 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66994806 |
| source | MEDLINE; Wiley Online Library Free Content; Access via Wiley Online Library; Access via ScienceDirect (Elsevier); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | 2-HP, 2-hydrazinopyridine AGE, advanced glycation endproduct Amine oxidase Amine Oxidase (Copper-Containing) - chemistry Amine Oxidase (Copper-Containing) - metabolism Antidepressive Agents - chemistry Antidepressive Agents - metabolism Binding Sites Copper metalloprotein Crystallography, X-Ray - methods CuAO, copper-containing amine oxidase ECAO, Escherichia coli amine oxidase Escherichia coli Escherichia coli - enzymology HuPAO, human plasma amine oxidase MAOI, flavin-containing monoamine oxidase inhibitor Models, Molecular Quinoprotein TCA, tricyclic antidepressant TCP, tranylcypromine TPQ, 2,4,5-trihydroxyphenylalanine quinone Tranylcypromine Tranylcypromine - chemistry Tranylcypromine - metabolism X-ray crystallography |
| title | Medical implications from the crystal structure of a copper-containing amine oxidase complexed with the antidepressant drug tranylcypromine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T20%3A49%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Medical%20implications%20from%20the%20crystal%20structure%20of%20a%20copper-containing%20amine%20oxidase%20complexed%20with%20the%20antidepressant%20drug%20tranylcypromine&rft.jtitle=FEBS%20letters&rft.au=Wilmot,%20Carrie%20M.&rft.date=2004-10-22&rft.volume=576&rft.issue=3&rft.spage=301&rft.epage=305&rft.pages=301-305&rft.issn=0014-5793&rft.eissn=1873-3468&rft_id=info:doi/10.1016/j.febslet.2004.09.031&rft_dat=%3Cproquest_cross%3E66994806%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20492653&rft_id=info:pmid/15498552&rft_els_id=S0014579304011378&rfr_iscdi=true |